Welcome to our dedicated page for SPRBD SEC filings (Ticker: SPRBD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SPRBD's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SPRBD's regulatory disclosures and financial reporting.
Spruce Biosciences director Daniel K. Spiegelman received a grant of stock options for 1,700 shares of Common Stock. The options have an exercise price of 52.7000 per share and expire on May 20, 2036. Following this grant, he holds 1,700 derivative securities directly.
The options vest on the first anniversary of the grant date, with full vesting no later than the company’s 2027 annual stockholder meeting, subject to his continuous service under the 2020 Equity Incentive Plan. The award will also vest in full upon a Change in Control as defined in that plan.
Spruce Biosciences director Daniel K. Spiegelman received a grant of stock options for 1,700 shares of Common Stock. The options have an exercise price of 52.7000 per share and expire on May 20, 2036. Following this grant, he holds 1,700 derivative securities directly.
The options vest on the first anniversary of the grant date, with full vesting no later than the company’s 2027 annual stockholder meeting, subject to his continuous service under the 2020 Equity Incentive Plan. The award will also vest in full upon a Change in Control as defined in that plan.
Spruce Biosciences director Camilla V. Simpson received a grant of stock options covering 1,700 shares of common stock. The options have an exercise price of $52.70 per share and expire on May 20, 2036. They generally vest on the first anniversary of the grant or by the company’s 2027 annual stockholder meeting, subject to continuous service, with full vesting upon a Change in Control.
Spruce Biosciences director Camilla V. Simpson received a grant of stock options covering 1,700 shares of common stock. The options have an exercise price of $52.70 per share and expire on May 20, 2036. They generally vest on the first anniversary of the grant or by the company’s 2027 annual stockholder meeting, subject to continuous service, with full vesting upon a Change in Control.
SPRUCE BIOSCIENCES, INC. Executive Chairman Michael G. Grey received a grant of stock options covering 1,700 shares of common stock at an exercise price of $52.70 per share. These options vest on the first anniversary of the grant date, will in any case be fully vested by the company’s 2027 annual stockholder meeting, and vest in full upon a Change in Control, all subject to his continuous service under the 2020 Equity Incentive Plan.
SPRUCE BIOSCIENCES, INC. Executive Chairman Michael G. Grey received a grant of stock options covering 1,700 shares of common stock at an exercise price of $52.70 per share. These options vest on the first anniversary of the grant date, will in any case be fully vested by the company’s 2027 annual stockholder meeting, and vest in full upon a Change in Control, all subject to his continuous service under the 2020 Equity Incentive Plan.
Spruce Biosciences director Percival Barretto-Ko received a grant of stock options covering 1,700 shares of Common Stock. The options have an exercise price of $52.70 per share and expire on May 20, 2036.
The grant vests on the first anniversary of the grant date and in any case will be fully vested by the company's 2027 annual stockholder meeting, subject to the director's continuous service under the 2020 Equity Incentive Plan. The options also vest in full upon a Change in Control.
Spruce Biosciences director Percival Barretto-Ko received a grant of stock options covering 1,700 shares of Common Stock. The options have an exercise price of $52.70 per share and expire on May 20, 2036.
The grant vests on the first anniversary of the grant date and in any case will be fully vested by the company's 2027 annual stockholder meeting, subject to the director's continuous service under the 2020 Equity Incentive Plan. The options also vest in full upon a Change in Control.
Spruce Biosciences director Keli Walbert received a new stock option grant. The Form 4 shows an award of 1,700 stock options for common stock at an exercise price of $52.70 per share, with 1,700 derivative securities held after the transaction.
The options vest on the first anniversary of the grant date and will in any case be fully vested by the company’s 2027 annual stockholder meeting, subject to continuous service. They also vest in full upon a change in control. This is a compensation-related grant, not an open-market purchase or sale.
Spruce Biosciences director Keli Walbert received a new stock option grant. The Form 4 shows an award of 1,700 stock options for common stock at an exercise price of $52.70 per share, with 1,700 derivative securities held after the transaction.
The options vest on the first anniversary of the grant date and will in any case be fully vested by the company’s 2027 annual stockholder meeting, subject to continuous service. They also vest in full upon a change in control. This is a compensation-related grant, not an open-market purchase or sale.
Spruce Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on May 21, 2026 in virtual format. As of the March 24, 2026 record date, 1,372,278 common shares were outstanding, and 903,893 shares, or about 65.86%, were represented, establishing a quorum.
Stockholders elected three Class III directors—Michael Grey, Camilla V. Simpson and Javier Szwarcberg—to serve until the 2029 annual meeting. They also ratified BDO USA, P.C. as independent auditor for the year ending December 31, 2026 and approved, on an advisory basis, the compensation of named executive officers.
In addition, stockholders indicated a preference for holding an advisory vote on executive compensation every year. The company plans to include an annual, non-binding say‑on‑pay vote in its proxy materials until the next required frequency vote, which must occur no later than the 2032 annual meeting.
Spruce Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on May 21, 2026 in virtual format. As of the March 24, 2026 record date, 1,372,278 common shares were outstanding, and 903,893 shares, or about 65.86%, were represented, establishing a quorum.
Stockholders elected three Class III directors—Michael Grey, Camilla V. Simpson and Javier Szwarcberg—to serve until the 2029 annual meeting. They also ratified BDO USA, P.C. as independent auditor for the year ending December 31, 2026 and approved, on an advisory basis, the compensation of named executive officers.
In addition, stockholders indicated a preference for holding an advisory vote on executive compensation every year. The company plans to include an annual, non-binding say‑on‑pay vote in its proxy materials until the next required frequency vote, which must occur no later than the 2032 annual meeting.
Spruce Biosciences (SPRB) ownership update: Alyeska Investment Group, L.P. and related filers report beneficial ownership of 61,670 shares of common stock, equal to 4.49% of the class as of March 31, 2026. The holding comprises 21,671 common shares, 9,999 shares issuable upon exercise of warrants, and 30,000 shares acquired in a private placement. The filing cites 1,372,043 shares outstanding per a Form 424B5 dated March 9, 2026. Alyeska Investment Group, L.P. discloses shared voting and dispositive power for the 61,670 shares, and Anand Parekh is identified as CEO of Alyeska Investment Group, L.P.; he disclaims beneficial ownership of certain shares held by Alyeska Master Fund, L.P.
Spruce Biosciences (SPRB) ownership update: Alyeska Investment Group, L.P. and related filers report beneficial ownership of 61,670 shares of common stock, equal to 4.49% of the class as of March 31, 2026. The holding comprises 21,671 common shares, 9,999 shares issuable upon exercise of warrants, and 30,000 shares acquired in a private placement. The filing cites 1,372,043 shares outstanding per a Form 424B5 dated March 9, 2026. Alyeska Investment Group, L.P. discloses shared voting and dispositive power for the 61,670 shares, and Anand Parekh is identified as CEO of Alyeska Investment Group, L.P.; he disclaims beneficial ownership of certain shares held by Alyeska Master Fund, L.P.
Spruce Biosciences ownership update: Squadron Master Fund LP, Squadron Capital Management, LLC and principals Matthew Sesterhenn and William Blank each report beneficial ownership of 12,200 shares of common stock, representing 0.9% of the class. The filings state these shares reflect shared voting and dispositive power, with no sole voting or dispositive power. The ownership percentage is based on 1,372,043 shares outstanding as of March 3, 2026. The statement includes an express disclaimer of beneficial ownership under Rule 13d-4. The amendment is signed by reporting persons on 05/15/2026.
Spruce Biosciences ownership update: Squadron Master Fund LP, Squadron Capital Management, LLC and principals Matthew Sesterhenn and William Blank each report beneficial ownership of 12,200 shares of common stock, representing 0.9% of the class. The filings state these shares reflect shared voting and dispositive power, with no sole voting or dispositive power. The ownership percentage is based on 1,372,043 shares outstanding as of March 3, 2026. The statement includes an express disclaimer of beneficial ownership under Rule 13d-4. The amendment is signed by reporting persons on 05/15/2026.
Spruce Biosciences, Inc. (Common Stock, CUSIP 85209E208) is reported as being beneficially owned in part by Wellington Management entities. The filing shows a 3.56% beneficial ownership position represented by shared voting power of 34,769 shares and shared dispositive power of 48,796. The Schedule 13G/A states these securities are owned of record by clients of Wellington Investment Advisers and lists the chain of parent and affiliate entities. The filing was signed by a compliance manager on 05/15/2026.
Spruce Biosciences, Inc. (Common Stock, CUSIP 85209E208) is reported as being beneficially owned in part by Wellington Management entities. The filing shows a 3.56% beneficial ownership position represented by shared voting power of 34,769 shares and shared dispositive power of 48,796. The Schedule 13G/A states these securities are owned of record by clients of Wellington Investment Advisers and lists the chain of parent and affiliate entities. The filing was signed by a compliance manager on 05/15/2026.
Spruce Biosciences reported a Q1 2026 net loss of $12.3 million, narrower than the $14.0 million loss a year earlier, as research and development spending declined. R&D totaled $7.6 million versus $10.8 million in Q1 2025, while general and administrative expenses rose to $4.4 million from $3.7 million.
As of March 31, 2026, Spruce held $54.1 million in cash and cash equivalents and had an accumulated deficit of $301.5 million. It also carried $16.6 million in gross debt under a new Avenue term loan, with $15.0 million funded at a 12.25% interest rate and secured by substantially all assets.
The company closed an April 2026 underwritten offering of 1,150,000 common shares and 50,000 pre-funded warrants, plus 180,000 additional shares from the underwriters’ option, for gross proceeds of about $69.0 million. Management believes existing cash plus these proceeds will fund planned operations and debt obligations for at least 12 months.
Spruce is focused on tralesinidase alfa enzyme replacement therapy (TA‑ERT) for mucopolysaccharidoses type IIIB, which has U.S. and EU orphan and breakthrough designations. The company plans to submit a biologics license application for TA‑ERT in the fourth quarter of 2026 and continues preclinical and clinical work on other candidates.
Spruce Biosciences reported a Q1 2026 net loss of $12.3 million, narrower than the $14.0 million loss a year earlier, as research and development spending declined. R&D totaled $7.6 million versus $10.8 million in Q1 2025, while general and administrative expenses rose to $4.4 million from $3.7 million.
As of March 31, 2026, Spruce held $54.1 million in cash and cash equivalents and had an accumulated deficit of $301.5 million. It also carried $16.6 million in gross debt under a new Avenue term loan, with $15.0 million funded at a 12.25% interest rate and secured by substantially all assets.
The company closed an April 2026 underwritten offering of 1,150,000 common shares and 50,000 pre-funded warrants, plus 180,000 additional shares from the underwriters’ option, for gross proceeds of about $69.0 million. Management believes existing cash plus these proceeds will fund planned operations and debt obligations for at least 12 months.
Spruce is focused on tralesinidase alfa enzyme replacement therapy (TA‑ERT) for mucopolysaccharidoses type IIIB, which has U.S. and EU orphan and breakthrough designations. The company plans to submit a biologics license application for TA‑ERT in the fourth quarter of 2026 and continues preclinical and clinical work on other candidates.